Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan von MATTESON, E. L, LOWE, V. J, PRENDERGAST, F. G, CROWSON, C. S, MODER, K. G, MORGENSTERN, D. E, MESSMANN, R. A, LOW, P. S

Volltext

CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC) von Morris, M.J., Vogelzang, N.J., Sartor, O., Armour, A., Messmann, R., Groaning, M., Robarts, A., Tolcher, A.W., Gordon, M., Babiker, H.M., Kuo, P., Kearney, M., Jendrisak, A., Wang, Y., Landers, M., Petrylak, D.P.

Volltext

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms von SAUSVILLE, Edward A, ARBUCK, Susan G, JING, Xiu-Xian, ROBERGE, Michel, FUSE, Eiichi, KUWABARA, Takashi, SENDEROWICZ, Adrian M, MESSMANN, Richard, HEADLEE, Donna, BAUER, Kenneth S, LUSH, Richard M, MURGO, Anthony, FIGG, William D, LAHUSEN, Tyler, JAKEN, Susan

Volltext

620 A Study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in Patients with Advanced Solid Tumors von Rasco, D.W, Patnaik, A, Amaya, A, Gaylor, S, Moore, T, Izbicka, E, Streeper, R, Rodrigueza, W, Messmann, R, Tolcher, A

Volltext

A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell... von Messmann, R A, Vitetta, E S, Headlee, D, Senderowicz, A M, Figg, W D, Schindler, J, Michiel, D F, Creekmore, S, Steinberg, S M, Kohler, D, Jaffe, E S, Stetler-Stevenson, M, Chen, H, Ghetie, V, Sausville, E A

Volltext

P-23 Phase II study (daNIS-3) of the anti–TGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone i... von Segal, N., Rivera, F., Tournigand, C., Kasper, S., Chen, Y., Deshpande, P., Messmann, R., Kopetz, S.

Volltext

OP 93 The co-development of a folate receptor molecular diagnostic imaging agent (99mTc-EC20) and folate receptor targeted drug conjugate (EC145) in the treatment of ovarian cancer... von Ghamande, S, Gilbert, L, Penson, R, Palmer, E, Scott, J, Symanowski, J, Messmann, R, Nguyen, B

Volltext

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials von Van Heertum, Ronald L, Scarimbolo, Robert, Wolodzko, John G, Klencke, Barbara, Messmann, Richard, Tunc, Feza, Sokol, Levi, Agarwal, Rajan, Strafaci, James A, O'Neal, Michael

Volltext

Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC) von Morris, M., Vogelzang, N.J., Sartor, O., Armour, A., Groaning, M., Messmann, R., Robarts, A., Petrylak, D.P., Tolcher, A., Gordon, M.S., Babiker, H.

Volltext

842PCTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC) von Morris, M J, Vogelzang, N J, Sartor, O, Armour, A, Messmann, R, Groaning, M, Robarts, A, Tolcher, A W, Gordon, M, Babiker, H M, Kuo, P, Kearney, M, Jendrisak, A, Wang, Y, Landers, M, Petrylak, D P

Volltext

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms von TAN, Antoinette R, HEADLEE, Donna, SENDEROWICZ, Adrian M, MESSMANN, Richard, SAUSVILLE, Edward A, ARBUCK, Susan G, MURGO, Anthony J, MELILLO, Giovanni, SUOPING ZHAI, FIGG, William D, SWAIN, Sandra M

Volltext

Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer von Symanowski, J. T., Maurer, A. H., Naumann, R. W., Shah, N. P., Morgenstern, D., Messmann, R. A.

Volltext

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cance... von Naumann, R. W., Symanowski, J. T., Ghamande, S. A., Gabrail, N. Y., Gilbert, L., Teneriello, M. G., Sutton, G., Lovejoy, C., Messmann, R. A.

Volltext

A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer von Harb, W. A., Conley, B. A., LoRusso, P., Sausville, E. A., Heath, E. I., Chandana, S. R., Hamm, M., Carter, J., Perez, W. J., Messmann, R. A.

Volltext

A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle von Sharma, S., Sausville, E. A., LoRusso, P., Vogelzang, N. J., Samlowski, W. E., Carter, J., Forman, K., Bever, S., Messmann, R. A.

Volltext

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cance... von Naumann, R. W., Coleman, R. L., Burger, R. A., Herzog, T. J., Morris, R., Sausville, E. A., Kutarska, E., Ghamande, S. A., Gabrail, N. Y., De Pasquale, S., Nowara, E., Gilbert, L., Caton, J. R., Gersh, R. H., Teneriello, M. G., Harb, W. A., Konstantinopoulos, P., Symanowski, J. T., Lovejoy, C., Messmann, R. A.

Volltext

A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors von Sausville, E., LoRusso, P., Quinn, M., Forman, K., Leamon, C., Morganstern, D., Bever, S., Messmann, R.

Volltext

Phase I trial of EC90 (keyhole-limpet hemocyanin fluorescein isothiocyanate conjugate) with GPI-0100 adjuvant followed by EC17 (Folate-Fluorescein Isothiocyanate Conjugate) in Pati... von Amato, R. J., Fagbeyiro, B., Messmann, R., Low, P. S.

Volltext

The Toxicity of Deglycosylated Ricin A Chain-containing Immunotoxins in Patients with Non-Hodgkin’s Lymphoma Is Exacerbated by Prior Radiotherapy: A Retrospective Analysis of Patie... von SCHINDLER, John, SAUSVILLE, Edward, MESSMANN, Richard, UHR, Jonathan W, VITETTA, Ellen S

Volltext

A phase II study of FolateImmune (EC90 with GP1–0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-α (IFN-α) in patients with refractory or... von Messmann, R., Amato, R., Hernandez-McClain, J., Conley, B., Rogers, H., Lu, J., Low, P., Bever, S., Morgenstern, D.

Volltext